Inflammatory Response
Conditions
Brief summary
The aim of the present study is to determine the effect of Iso-alpha-Acids and Xanthohumol from hops on the immune response of healthy participants over a timeframe of 6 hours.
Detailed description
In this placebo-controlled crossover study a study drink enriched with either a placebo, Xanthohumol, Iso-alpha Acids or a combination of latter is given to the participants. A washout phase before intervention and between each intervention is introduced. On day one of each intervention blood is drawn in fasted state from each participant. Subsequently the study drink combined with a standardized breakfast is given to the participants followed by blood draws 1, 2, 3, 4 and 6 hours after the consumption of the study drink. To assess the effect of Xanthohumol and Iso-alpha acids or a combination of both, clinical parameters, blood lipids, blood glucose, uric acid and inflammatory markers will be determined. Furthermore, blood cells, isolated from blood samples of each time point, will be stimulated for measuring inflammatory markers.
Interventions
DIETARY_SUPPLEMENTXanthohumol
Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)
DIETARY_SUPPLEMENTIso-alpha-Acids
Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
DIETARY_SUPPLEMENTXanthohumol + Iso-alpha-Acids
Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
Sponsors
University of Vienna
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy * BMI: \>18,5 kg/m² or \<30 kg/m²
Exclusion criteria
* food intolerances * food allergies * chronic inflammatory diseases * metabolic diseases * viral or bacterial infections within the last 3 weeks of inclusion * intake of immunosuppressive medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in parameters of immune response | 6 hours | Changes in concentration of interleukin 6 (ng/ml) in cell culture supernatant of stimulated cells. |
Countries
Austria
Contacts
Primary ContactIna Bergheim, Prof. Dr.
Outcome results
None listed